What of us? I thought we could ride this drug for a couple more years!
-
Mon news: Takeda layoffs. Novo’s semaglutide cardiovascular win. Roche’s Vabysmo in DME. Gilead/Merck HIV combo. Supernus quick-acting depression med. See more on our front page
Crestor reps!
- Thread starter Anonymous
- Start date
-
- Tags
- None
Who says you're losing the job? At this late stage AZ is not going to be repalcing reps. They'll keep what they have for the duration of the patent and hope for miraculous results. Hang in there. In my assumption, real fear is for the Overlays, and PT reps..
CRESTOR exclusivity will run to 2030 with CRESTOR/Vascepa combo, your job is safe if they can land the deal before GSK or Pfizer.
Your job is safe with the CRESTOR/Icosapent combo drug until 2030.
Overlays - no matter the therapeutic area need to GO!!!!!! Talk about lack of accountability and they laugh all the way to bank.
What part don't you morons get? 40% of revenue gone. 40% of reps gone.
Nothing coming until 2016-2018. Lay you off and maybe, just maybe rehire when
revenue gets better. IF revenue gets better.
Glaxo has Lovaza. They won't get Vascepa. You'll have generic Crestor with
Vascepa. Think insurance will pay for that? Obamacare in full swing by then.
Will save money anyway they can.
Contract is the way to go. Two years ago AZ said any specialty products they will
give to their reps. Any primary care drug they will give to contract force.
Sorry, game over.
Nothing coming until 2016-2018. Lay you off and maybe, just maybe rehire when
revenue gets better. IF revenue gets better.
Glaxo has Lovaza. They won't get Vascepa. You'll have generic Crestor with
Vascepa. Think insurance will pay for that? Obamacare in full swing by then.
Will save money anyway they can.
Contract is the way to go. Two years ago AZ said any specialty products they will
give to their reps. Any primary care drug they will give to contract force.
Sorry, game over.
Agreed. Listen, I experienced 3 layoffs in 5 years at AZ and the denial is part of the process. Nothing can be done other than further cuts based on billions in lost revenues over the next few years. Seroquel-Gone, Nexium-Gone next year, Crestor-market share erosion from atorva, gone by 2016.....obummercare in full swing next year. What is left? It does not take an expert to see what is happening and admit that AZ is disintegrating along with thousands of jobs.
Vascepa/statin sNDA would receive 3 yrs of exclusivity, then would coast on the patent when approved to 2030. Amarin recently changed statin from Atorvastatin to Rosuvastatin. AHA is recommending heart patients take combo pills to simplify regimen. Crestor is tier 2 now and Vascepa is tier 3 (some 2) after 7 weeks post launch. Vascepa's weekly sales have also surpassed Brilinta (the future best seller?
CRESTOR's game is NOT over.
"December 17, 2012
Amarin Announces Completion of Dosing in a Fixed-Dose Combination Study With Vascepa(R) and a Leading Statin
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has completed dosing and pharmacokinetic sampling in a study to test a fixed-dose combination of Vascepa® (icosapent ethyl) capsules and a leading statin. The clinical name for this combination product is AMR102. Prior to commencement of the study, Amarin opened an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration which became effective after the standard 30-day review.
The purpose of this AMR102 study is to determine the bioavailability of the EPA (eicosapentaenoic acid) and statin components when taken as a fixed-dose combination product, relative to the individual reference agents taken concomitantly. Statin bioavailability from both the fixed-dose and concomitant regimens will also be compared with that from the reference statin taken alone in healthy subjects. Additionally, pharmacokinetic data from this study will be examined to explore relationships between in vitro dissolution data and in vivo pharmacokinetic data. The study is designed as a randomized, open-label, multiple dose, parallel-group study in 48 healthy subjects conducted at a single site in the United States.
"This study is aimed at expanding the potential commercial application of Vascepa by leveraging the clinical successes of the MARINE and ANCHOR trials, namely effective triglyceride lowering without increasing LDL-C," stated Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin's goal is to identify ways for patients to simplify their lipid management by developing a single therapy that offers the powerful triglyceride lowering effects of Vascepa combined with one of the most prescribed statin products."
Amarin looks forward to analyzing the results from this study and expects to communicate such results in the first half of 2013."
Vascepa/statin sNDA would receive 3 yrs of exclusivity, then would coast on the patent when approved to 2030. Amarin recently changed statin from Atorvastatin to Rosuvastatin. AHA is recommending heart patients take combo pills to simplify regimen. Crestor is tier 2 now and Vascepa is tier 3 (some 2) after 7 weeks post launch. Vascepa's weekly sales have also surpassed Brilinta (the future best seller?
CRESTOR's game is NOT over.
"December 17, 2012
Amarin Announces Completion of Dosing in a Fixed-Dose Combination Study With Vascepa(R) and a Leading Statin
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has completed dosing and pharmacokinetic sampling in a study to test a fixed-dose combination of Vascepa® (icosapent ethyl) capsules and a leading statin. The clinical name for this combination product is AMR102. Prior to commencement of the study, Amarin opened an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration which became effective after the standard 30-day review.
The purpose of this AMR102 study is to determine the bioavailability of the EPA (eicosapentaenoic acid) and statin components when taken as a fixed-dose combination product, relative to the individual reference agents taken concomitantly. Statin bioavailability from both the fixed-dose and concomitant regimens will also be compared with that from the reference statin taken alone in healthy subjects. Additionally, pharmacokinetic data from this study will be examined to explore relationships between in vitro dissolution data and in vivo pharmacokinetic data. The study is designed as a randomized, open-label, multiple dose, parallel-group study in 48 healthy subjects conducted at a single site in the United States.
"This study is aimed at expanding the potential commercial application of Vascepa by leveraging the clinical successes of the MARINE and ANCHOR trials, namely effective triglyceride lowering without increasing LDL-C," stated Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin's goal is to identify ways for patients to simplify their lipid management by developing a single therapy that offers the powerful triglyceride lowering effects of Vascepa combined with one of the most prescribed statin products."
Amarin looks forward to analyzing the results from this study and expects to communicate such results in the first half of 2013."
"BOLT-ON AQUISTION"
Looks like we'll be selling Vascepa!! Bring it on, I'm ready to sell something new. The combo product looks great, too. This means solid employment until at least 2030.
WTF r you talking about! Pfizer? Combo patent is with Atorvastatin, fucking CRESTOR is FUCKED!!! AZN should have picked off Amarin after phase 3 Anchor was released. Now CRESTOR's $5 B revenue is gone in 2016 in the US and quicker than that in ROW.
You mean I've got 17 more years to ride this bad boy!!!
Thank you, thank you, thank you!!!
Thank you, thank you, thank you!!!
I wonder.....AZ launched " Toprol-xl w/ HCT " with contract force and it bombed.....hard to know if it was the drug, our dumb strategy or the contract sales force ? ( contract is just that contract..... aka a sales force with a temporary mind set)
I can't believe it bombed it was almost cheaper than the two generics it was made up of and generic xl was on back order for a good majority of the launch.
And where was this announced? There have been so many numbers mentioned that I can't keep up anymore?
Look it up at Patent PAIRs. http://portal.uspto.gov/pair/PublicPair
#13417899
https://dl.dropbox.com/u/57678878/13417899 Claims.pdf
"The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same."
03-27-2013 Reasons for Allowance
And another:
#13124628
https://dl.dropbox.com/u/57678878/Co formulated with Crestor 13124628.pdf